First Personal Financial Services Has $1.30 Million Position in Laboratory Corporation of America Holdings (LH)

First Personal Financial Services cut its stake in shares of Laboratory Corporation of America Holdings (NYSE:LH) by 4.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,403 shares of the medical research company’s stock after selling 356 shares during the period. First Personal Financial Services’ holdings in Laboratory Corporation of America Holdings were worth $1,295,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Regentatlantic Capital LLC raised its stake in Laboratory Corporation of America Holdings by 0.5% in the second quarter. Regentatlantic Capital LLC now owns 1,696 shares of the medical research company’s stock valued at $261,000 after buying an additional 8 shares in the last quarter. Endurance Wealth Management Inc. raised its stake in Laboratory Corporation of America Holdings by 0.7% in the first quarter. Endurance Wealth Management Inc. now owns 1,510 shares of the medical research company’s stock valued at $217,000 after buying an additional 10 shares in the last quarter. Oppenheimer & Co. Inc. raised its stake in Laboratory Corporation of America Holdings by 0.6% in the first quarter. Oppenheimer & Co. Inc. now owns 2,411 shares of the medical research company’s stock valued at $346,000 after buying an additional 15 shares in the last quarter. New Amsterdam Partners LLC NY raised its stake in Laboratory Corporation of America Holdings by 0.7% in the second quarter. New Amsterdam Partners LLC NY now owns 3,847 shares of the medical research company’s stock valued at $593,000 after buying an additional 27 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. raised its stake in Laboratory Corporation of America Holdings by 0.8% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 4,143 shares of the medical research company’s stock valued at $594,000 after buying an additional 31 shares in the last quarter. Institutional investors own 91.64% of the company’s stock.

Laboratory Corporation of America Holdings (NYSE:LH) opened at 154.56 on Friday. Laboratory Corporation of America Holdings has a 52 week low of $119.51 and a 52 week high of $164.22. The company has a market capitalization of $15.73 billion, a PE ratio of 21.65 and a beta of 0.94. The company has a 50-day moving average of $155.84 and a 200-day moving average of $144.91.

Laboratory Corporation of America Holdings (NYSE:LH) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.47 EPS for the quarter, beating the Zacks’ consensus estimate of $2.40 by $0.07. Laboratory Corporation of America Holdings had a net margin of 7.57% and a return on equity of 16.85%. The company had revenue of $2.50 billion for the quarter, compared to analysts’ expectations of $2.47 billion. During the same period in the prior year, the company posted $2.36 EPS. Laboratory Corporation of America Holdings’s revenue was up 4.9% compared to the same quarter last year. On average, equities research analysts anticipate that Laboratory Corporation of America Holdings will post $9.51 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.com-unik.info/2017/08/18/first-personal-financial-services-has-1-30-million-position-in-laboratory-corporation-of-america-holdings-lh.html.

Several brokerages have recently commented on LH. Craig Hallum reissued a “buy” rating and issued a $179.00 target price (up from $157.00) on shares of Laboratory Corporation of America Holdings in a report on Thursday, July 27th. Credit Suisse Group downgraded Laboratory Corporation of America Holdings to a “hold” rating and set a $146.00 price target on the stock. in a research note on Thursday, July 13th. They noted that the move was a valuation call. Barclays PLC reissued an “overweight” rating and issued a $182.00 price target (up previously from $175.00) on shares of Laboratory Corporation of America Holdings in a research note on Monday, July 17th. BidaskClub raised Laboratory Corporation of America Holdings from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, June 28th. Finally, Morgan Stanley upped their price objective on shares of Laboratory Corporation of America Holdings from $154.00 to $166.00 and gave the company an “overweight” rating in a research report on Thursday, August 10th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $159.75.

In other Laboratory Corporation of America Holdings news, SVP Lance Berberian sold 3,613 shares of the stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $139.84, for a total value of $505,241.92. Following the sale, the senior vice president now directly owns 5,789 shares in the company, valued at approximately $809,533.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director R Sanders Williams sold 3,100 shares of the stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $156.88, for a total transaction of $486,328.00. Following the completion of the sale, the director now owns 10,073 shares in the company, valued at $1,580,252.24. The disclosure for this sale can be found here. Insiders sold a total of 17,681 shares of company stock worth $2,743,227 over the last quarter. Corporate insiders own 0.90% of the company’s stock.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corporation of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

What are top analysts saying about Laboratory Corporation of America Holdings? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Laboratory Corporation of America Holdings and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit